- Home
- ELEV vs LPCN Comparison
ELEV vs LPCN Comparison
Compare ELEV & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- LPCN
- Stock Information
- Founded
- ELEV 2019
- LPCN 1997
- Country
- ELEV United States
- LPCN United States
- Employees
- ELEV N/A
- LPCN N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- LPCN Health Care
- Exchange
- ELEV Nasdaq
- LPCN Nasdaq
- Market Cap
- ELEV 34.0M
- LPCN 36.8M
- IPO Year
- ELEV 2021
- LPCN N/A
- Fundamental
- Price
- ELEV $0.61
- LPCN $5.00
- Analyst Decision
- ELEV Strong Buy
- LPCN Strong Buy
- Analyst Count
- ELEV 5
- LPCN 1
- Target Price
- ELEV $7.80
- LPCN $10.00
- AVG Volume (30 Days)
- ELEV 673.9K
- LPCN 26.8K
- Earning Date
- ELEV 11-06-2024
- LPCN 11-07-2024
- Dividend Yield
- ELEV N/A
- LPCN N/A
- EPS Growth
- ELEV N/A
- LPCN N/A
- EPS
- ELEV N/A
- LPCN N/A
- Revenue
- ELEV N/A
- LPCN $7,922,926.00
- Revenue This Year
- ELEV N/A
- LPCN N/A
- Revenue Next Year
- ELEV N/A
- LPCN N/A
- P/E Ratio
- ELEV N/A
- LPCN N/A
- Revenue Growth
- ELEV N/A
- LPCN N/A
- 52 Week Low
- ELEV $0.44
- LPCN $2.38
- 52 Week High
- ELEV $5.83
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- ELEV 51.53
- LPCN 46.99
- Support Level
- ELEV $0.52
- LPCN $4.64
- Resistance Level
- ELEV $0.70
- LPCN $5.40
- Average True Range (ATR)
- ELEV 0.06
- LPCN 0.54
- MACD
- ELEV 0.00
- LPCN -0.10
- Stochastic Oscillator
- ELEV 41.81
- LPCN 24.06
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.